Acrivon Therapeutics

Observed pricing power is absent pre‑approval, but potential is meaningful. If ACR‑368 delivers confirmatory efficacy in a high‑mortality endometrial cancer subset with a required diagnostic, U.S. oncology pricing norms could support robust gross margins.

The diagnostic pairing and Fast Track/Breakthrough Device status may reduce payer friction if clinical benefit is clear. Latent pricing power is therefore moderate-to-high in a success case, but entirely binary on clinical and regulatory outcomes.